A Single-Center, Phase 2a, Randomized, Double Masked, Clinical Study to Assess the Safety, Tolerability, and Pharmacodynamic Activity of ADX-102 Ophthalmic Solution in Subjects With Dry Eye Syndrome
Phase of Trial: Phase II
Latest Information Update: 25 Oct 2017
At a glance
- Drugs Reproxalap (Primary)
- Indications Dry eyes
- Focus Adverse reactions
- Sponsors Aldeyra Therapeutics
- 17 Oct 2017 Status changed from active, no longer recruiting to completed.
- 10 Oct 2017 According to an Aldeyra Therapeutics media release, data will be presented at the 2017 Research & Development Day.
- 12 Sep 2017 Results published in an Aldeyra Therapeutics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History